author-photo

Anke Mütherig

German Cancer Research Center

5

Papers

133

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (123)
Minimal-Residual Disease Guided Treatment with Azacitidine in MDS/AML Patients at Imminent Risk of Relapse: Results of the Prospective RELAZA2 Trial

2017 Blood
Show All
- Source
- Cite
- Save
Citations (6)